ClinicalTrials.gg
Sign In

Biological

Pembrolizumab/Quavonlimab MK-1308A clinical trials

Also written MK-1308A.

studies test it
10
open now
0
in phase 3
2
first study started
2017

How studies write it

Studies that test it under each name

Name

Pembrolizumab/Quavonlimab
9

Development codes

MK-1308A
10

Studies by the year they started

10 studies that test it; most in 2021 (5)

Studies that test Pembrolizumab/Quavonlimab MK-1308A, by start year
YearStudies
20171
20203
20215
20221

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
8
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Renal Cell
4
Melanoma
2
Colorectal Neoplasms
1
Small Cell Lung Carcinoma
1
Neoplasms
1

Who runs them

Industry 10 · Other 0

Merck Sharp & Dohme LLC (10)

Often tested with

Tested in the same studies.

Pembrolizumab (8) · Belzutifan (4) · Favezelimab (4) · Lenvatinib (4) · Vibostolimab (2) · Anti-ILT4 Monoclonal Antibody MK-4830 (1) · Favezelimab/Pembrolizumab Formulation (1) · Raludotatug deruxtecan (1)

Studies

Open first, then newest update. How each study uses Pembrolizumab/Quavonlimab MK-1308A is read from its arms, and is right about nine times in ten.

Testing it · 10